What Is New in the GCC Medical Devices Regulation: 2026 Updates

This blog was originally posted on 10th July, 2026. Further regulatory developments may have occurred after publication. To keep up-to-date with the latest compliance news, sign up to our newsletter.

AUTHORED BY NEDAA YOUSEF, REGULATORY COMPLIANCE ANALYST, ADHERENT

---

The GCC medical device market is entering a new regulatory era. For many years, market access across the Gulf was largely driven by reliance on approvals granted by established foreign regulators. Manufacturers could often leverage existing EU, US, or other international authorizations to support registration processes, while local distributors managed much of the in-country regulatory burden.

That approach is becoming increasingly obsolete.

Across the GCC, regulators are building more sophisticated frameworks that prioritize local oversight, supply chain visibility, post-market surveillance, and clinical accountability. The focus is no longer limited to whether a device has been approved elsewhere. Instead, authorities increasingly want visibility into how products are registered, distributed, monitored, investigated, and recalled within their own jurisdictions.

Recent developments across Saudi Arabia, the UAE, Bahrain, Kuwait, and Qatar illustrate this shift. While each country has introduced different reforms, the direction of travel is remarkably consistent. Saudi Arabia is placing greater emphasis on technical documentation and portfolio governance. Bahrain is implementing digital traceability infrastructure. The UAE is centralizing oversight under a dedicated federal regulator. Kuwait is strengthening post-market controls and recall requirements. Qatar is expanding oversight of clinical research involving medical devices.

Taken together, these developments demonstrate a broader regional trend: GCC regulators are seeking greater visibility into products, manufacturers, supply chains, and clinical activities occurring within their jurisdictions. For manufacturers, authorized representatives, and distributors, maintaining market access increasingly requires a permanent compliance presence supported by robust regulatory processes, local expertise, and proactive lifecycle management.

Table of Contents

• The Saudi Route: Raising the Bar for Technical Documentation
• Bahrain’s New Traceability System
• The EDE Era: UAE Transfer of Responsibilities
• Kuwait’s Compliance Framework: Medical Device Safety in 2026
• Qatar’s Clinical Research Framework
• GCC Regulation Is Becoming a Competitive Differentiator Research Framework

The Saudi Route: Raising the Bar for Technical Documentation

It has been about six years since Saudi Arabia started moving away from the historical GHTF-reliance model and toward Technical File Assessment (TFA) as the basis for review. In practice, this means manufacturers must increasingly demonstrate the safety, performance, and intended use of their devices through robust technical documentation rather than relying solely on approvals obtained in other jurisdictions. As Saudi Arabia continues to mature its regulatory framework, submission quality and portfolio strategy are becoming increasingly important factors in achieving efficient market access.

Recent 2026 regulatory guidance continues to discuss MDMA applications in terms of technical-documentation review rather than automatic reliance on foreign approvals.  In May 2026, SFDA issued MDS-G-028, which updates the rules for when multiple devices can be included in a single MDMA application.  This replaces earlier bundling criteria and provides more detailed rules for device families, systems, procedure packs, and IVDs. For companies with large portfolios, this can significantly affect submission strategy and costs.

The guidance may require manufacturers to reassess existing registration approaches, particularly where broad product portfolios have historically been grouped under fewer applications. Consequently, regulatory planning in Saudi Arabia is becoming increasingly intertwined with commercial portfolio management. 

Bahrain’s New Traceability System

Bahrain’s 2026 reforms highlight another defining trend across the GCC: the growing importance of supply chain transparency and digital traceability. Regulators increasingly expect manufacturers to maintain visibility over products after they enter the market, creating new compliance obligations for manufacturers, importers, and distributors alike. 

Bahrain’s National Health Regulatory Authority (NHRA) introduced a new digital compliance framework for medical devices and medical supplies through the launch of the TATABU Traceability Programme and the rollout of the MADAR 2.0 platform. Together, these initiatives establish mandatory registration, enhanced traceability requirements, and a centralized digital pathway for regulatory submissions.

For manufacturers, authorized representatives, and distributors, the new framework increases obligations related to registration, onboarding, and supply chain transparency. With full implementation of the traceability regime beginning in July 2026, companies operating in Bahrain must increasingly view regulatory compliance and supply chain management as interconnected functions rather than separate operational activities.

The EDE Era: UAE Transfer of Responsibilities

While Saudi Arabia is increasing technical scrutiny and Bahrain is investing in traceability, the UAE is pursuing a different objective: regulatory centralization. The transfer of responsibilities to the Emirates Drug Establishment (EDE) represents one of the most significant institutional reforms in the region’s healthcare regulatory landscape. 

In December 2025, MOHAP formally announced the transfer of key regulatory services to EDE, reinforcing the implementation of Federal Decree-Law No. 38 of 2024 and consolidating oversight of medical products under a single authority.

This transition forms part of a broader effort to centralize healthcare product regulation and establish a more unified regulatory ecosystem. Manufacturers seeking market access in the UAE now increasingly interact with EDE for product registrations, marketing authorizations, import permits, and post-market compliance activities.

For industry stakeholders, the practical significance extends beyond administrative restructuring. Companies must monitor evolving procedures, digital platforms, and compliance expectations as EDE continues to develop its operational framework. These changes are expected to influence regulatory planning, submission pathways, and lifecycle management strategies for medical device companies operating in the region.

Kuwait’s Compliance Framework: Medical Device Safety in 2026

Kuwait’s recent reforms reflect a broader regional focus on lifecycle governance. Regulators are increasingly concerned not only with market entry, but also with how products are monitored, recalled, priced, and managed throughout their commercial lifespan. 

Published in January 2026, two Ministerial Decisions introduced new requirements for product recalls, registration controls, and pricing oversight for medical products, including medical devices. The measures strengthen post-market surveillance, establish clearer procedures for withdrawals, suspensions, and cancellations, and expand electronic reporting and pricing compliance obligations. 

For manufacturers and authorized representatives, these developments increase the focus on lifecycle management, regulatory compliance, and market surveillance activities throughout the product’s time on the Kuwaiti market.

Qatar’s Clinical Research Framework

As GCC regulators place greater emphasis on evidence-based healthcare, Qatar is expanding oversight of clinical research involving medical devices. The country’s latest reforms demonstrate a growing expectation that manufacturers and sponsors maintain robust governance throughout the research and investigation process. 

Published in May 2026, the Executive Regulation of Law No. 6 of 2025 brings medical devices within Qatar’s broader health research and clinical trials framework. Recent regulatory developments place increased emphasis on clinical trial oversight, documentation requirements, product traceability, and quality standards for devices used in research settings.

For manufacturers and sponsors conducting clinical investigations in Qatar, these changes introduce additional compliance considerations that may affect study planning, regulatory submissions, and market access strategies.

GCC Regulation Is Becoming a Competitive Differentiator Research Framework

Taken individually, the reforms introduced across Saudi Arabia, Bahrain, the UAE, Kuwait, and Qatar may appear to address different regulatory objectives. Taken together, however, they reveal a common direction of travel: greater regulatory maturity, increased local oversight, and stronger expectations for lifecycle compliance.

The implications for manufacturers are significant. The GCC can no longer be viewed as a secondary export destination where products enter the market through a distributor-led registration process. Regulatory authorities are increasingly demanding direct accountability from manufacturers through enhanced technical reviews, digital traceability requirements, post-market surveillance obligations, and clinical oversight frameworks.

As a result, regulatory capability is becoming a competitive differentiator. Manufacturers that continue to treat GCC approvals as an extension of their EU or US regulatory strategy may find themselves struggling to keep pace with evolving local requirements. By contrast, companies that invest in regional regulatory expertise, sophisticated authorized representative networks, and long-term compliance infrastructure will be better positioned to secure and maintain market access across the Gulf.

What This Means for Manufacturers

To remain competitive in an increasingly regulated GCC market, manufacturers should consider the following priorities:

• Move Beyond a Registration-Centric Approach
  • Treat market authorization as the beginning of the compliance journey rather than the end.
  • Plan for ongoing obligations such as post-market surveillance, adverse event reporting, field safety corrective actions, and product traceability.
  • Allocate resources for long-term lifecycle management across all GCC markets.

• Invest in Local Regulatory Capability
  • Ensure authorized representatives and local partners have the expertise needed to navigate evolving regulatory requirements.
  • Verify that local partners can support digital registration platforms, traceability systems, and post-market compliance activities.
  • Regularly review local compliance arrangements as regulatory expectations continue to evolve.
• Integrate Regulatory and Supply Chain Planning
  • Align regulatory, logistics, and commercial teams to minimize disruptions.
  • Consider the impact of registration timelines, import controls, and traceability requirements on inventory management and product availability.
  • Build resilience into supply chains to mitigate operational and geopolitical risks.
• Prepare for Greater Regional Regulatory Maturity
  • Monitor regulatory developments across the GCC rather than focusing solely on individual markets.
  • Establish scalable compliance processes that can adapt to new requirements.
  • Anticipate increased scrutiny of technical documentation, post-market activities, and product traceability.

The GCC remains one of the world’s fastest-growing medical technology markets, supported by significant healthcare investment and rising demand for innovative medical products. However, market access is becoming increasingly dependent on regulatory capability. As authorities strengthen technical review, traceability, post-market oversight, and clinical governance requirements, manufacturers that embed compliance into their long-term regional strategy will be best positioned to succeed. 

See Adherent in Action

Discover how agentic AI is reshaping product compliance for global enterprises.

Book a Demo